CN105381272A - 一种治疗骨关节炎的中药汤剂及其制备方法 - Google Patents
一种治疗骨关节炎的中药汤剂及其制备方法 Download PDFInfo
- Publication number
- CN105381272A CN105381272A CN201510985344.7A CN201510985344A CN105381272A CN 105381272 A CN105381272 A CN 105381272A CN 201510985344 A CN201510985344 A CN 201510985344A CN 105381272 A CN105381272 A CN 105381272A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- herba
- rhizoma
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 13
- 241001438943 Callicarpa kwangtungensis Species 0.000 claims description 18
- 241000005787 Cistanche Species 0.000 claims description 18
- 241000218176 Corydalis Species 0.000 claims description 18
- 239000009636 Huang Qi Substances 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 16
- 239000012567 medical material Substances 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 230000000149 penetrating effect Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 6
- 240000000031 Achyranthes bidentata Species 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 238000012859 sterile filling Methods 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 12
- 210000000988 bone and bone Anatomy 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 210000003205 muscle Anatomy 0.000 abstract description 3
- 241000220436 Abrus Species 0.000 abstract 1
- 240000004539 Alocasia cucullata Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 240000003690 Callicarpa japonica Species 0.000 abstract 1
- 235000017595 Callicarpa japonica Nutrition 0.000 abstract 1
- 241000336291 Cistanche deserticola Species 0.000 abstract 1
- 241000437896 Corydalis bungeana Species 0.000 abstract 1
- 241000208688 Eucommia Species 0.000 abstract 1
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 241000001522 Terminalia chebula Species 0.000 abstract 1
- 235000011517 Terminalia chebula Nutrition 0.000 abstract 1
- 241001643425 Tinospora sinensis Species 0.000 abstract 1
- 235000008326 Trichosanthes anguina Nutrition 0.000 abstract 1
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 230000002875 effect on osteoarthritis Effects 0.000 abstract 1
- 239000010135 fructus aurantii immaturus Substances 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000000629 knee joint Anatomy 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 11
- 208000006820 Arthralgia Diseases 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 206010023215 Joint effusion Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 3
- 229960000590 celecoxib Drugs 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 229960004590 diacerein Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 201000001819 hydrarthrosis Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- -1 sublimed preparation Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000521257 Hydrops Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000013546 non-drug therapy Methods 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000004879 turbidimetry Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000020307 Spinal disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗骨关节炎的中药汤剂及其制备方法，所述中药由下述重量份数的药材制成：怀牛膝17-35份，黄芪12-29份，鸡骨草8-16份，瓜蒌子11-24份，肉苁蓉10-18份，西青果5-12份，苦玄参15-28份，宽筋藤7-16份，广东紫珠3-9份，天麻5-15份，苦地丁4-16份，枳壳5-21份，卜芥9-23份，川射干10-19份，杜仲12-28份。本发明的中药组合物具有补肾益精、气血双补、活血化瘀、通络强筋、祛风除湿、止痛祛痹作用，对多种病因引起的骨关节炎具有显著的治疗效果；本发明所选材料皆为传统中药材料，药源易得，疗效显著，无任何毒副作用。
Description
技术领域
本发明涉及一种治疗骨关节炎的中药，属于医药技术领域。
背景技术
骨关节炎是以关节软骨退变为主的病理改变，临床以关节疼痛、肿胀、及活动受限为主要症状的慢性骨关节病。发病机制受年龄因素、遗传因素、外部刺激等因素的多重作用导致滑膜、软骨和骨的代谢改变，进而产生炎症。
骨关节炎的另一个症状为关节积液。手术能较好的排出积液并能有效防止在手术过程中造成感染，但是手术费用高昂。且手术排出关节积液为治标不治本的方式，无法根除病症，一段时间过后，关节积液往复出现。
中医认为，骨关节炎属于“骨痹”范畴。认为其发病不外乎外感风寒湿邪，内伤于肝肾不足，气血失和或有跌仆损伤，均使气血运行不畅，络脉阻滞不通，病久则肝肾两亏，筋软骨萎，功能障碍。该疾患的治疗，主要为中西药物治疗和非药物治疗，其中非药物治疗为患者健康教育、自我训练、关节活动度训练、肌力训练、助行工具的使用、膝内翻的楔行鞋垫、职业治疗及关节保护、日常生活的辅助设施等；药物治疗包括：透明质酸钠关节腔内注射，口服氨基葡萄糖，口服或外用非甾体镇痛抗炎药。
发明内容
本发明所要解决的技术问题是：提供一种治疗骨关节炎的纯中药配方，该中药组合物配制方便、疗效显著、无副作用。
为解决上述技术问题，本发明采用的技术方案是：
提供的治疗骨关节炎的中药汤剂由下述重量份数的药材制成：怀牛膝17-35份，黄芪12-29份，鸡骨草8-16份，瓜蒌子11-24份，肉苁蓉10-18份，西青果5-12份，苦玄参15-28份，宽筋藤7-16份，广东紫珠3-9份，天麻5-15份，苦地丁4-16份，枳壳5-21份，卜芥9-23份，川射干10-19份，杜仲12-28份。
优选的，所述重量份数的药材制成：怀牛膝20-30份，黄芪15-25份，鸡骨草10-14份，瓜蒌子13-20份，肉苁蓉12-16份，西青果7-10份，苦玄参17-25份，宽筋藤9-14份，广东紫珠4-8份，天麻7-13份，苦地丁5-15份，枳壳8-18份，卜芥12-20份，川射干12-17份，杜仲15-25份。
进一步的，所述中药由下述重量份数的药材制成：怀牛膝25份，黄芪20份，鸡骨草12份，瓜蒌子17份，肉苁蓉14份，西青果10份，苦玄参21份，宽筋藤12份，广东紫珠6份，天麻10份，苦地丁10份，枳壳13份，卜芥16份，川射干15份，杜仲20份。
进一步的，所述中药由下述重量份数的药材制成：怀牛膝35份，黄芪29份，鸡骨草16份，瓜蒌子24份，肉苁蓉18份，西青果12份，苦玄参28份，宽筋藤16份，广东紫珠9份，天麻15份，苦地丁16份，枳壳21份，卜芥23份，川射干19份，杜仲28份。
进一步的，所述中药由下述重量份数的药材制成：怀牛膝17份，黄芪12份，鸡骨草8份，瓜蒌子11份，肉苁蓉10份，西青果5份，苦玄参15份，宽筋藤7份，广东紫珠3份，天麻5份，苦地丁4份，枳壳5份，卜芥9份，川射干10份，杜仲12份。
为了更好地表达本发明的中药组合物，本发明的中药组合物可以制备成临床上常用的剂型。比如，粉状制剂、散剂、丸剂、丹剂、膏剂、颗粒剂、口服液、糖浆、片剂、胶囊剂等制剂，所述药物制剂均可按照本领域技术人员所熟知的中药制剂制备方法制备得到。优选的，本发明中药组合物按照常规制备工艺制备成汤剂、片剂或胶囊剂。
本发明还提供了一种上述所述中药组合物的制备方法，其主要包含下述步骤：将所述配方量中药怀牛膝、黄芪、鸡骨草、瓜蒌子、肉苁蓉、西青果、苦玄参、宽筋藤、广东紫珠、天麻、苦地丁、枳壳、卜芥、川射干、杜仲粉碎，过100-130目筛，得细粉；将粉混合均匀，置于通透袋内，用温度为25-35℃的清水浸泡24小时（优选22小时），用水量为所述细粉量的6倍；武火煮沸，文火煎煮50分钟后取出通透袋，所得液体浓缩至原体积的0.3-0.5倍，得浓缩液；浓缩液中可加入适量的蜂蜜，得到混合液，所得混合液无菌灌装，每袋100mL，既得中药汤剂。
本发明的中药为口服，服用方法：每日三次，每次1袋，饭后1小时后温服。14天为1个疗程。
有益效果：本发明的中药组合物具有补肾益精、气血双补、活血化瘀、通络强筋、祛风除湿、止痛祛痹作用，对多种病因引起的骨关节炎具有显著的治疗效果；本发明所选材料皆为传统中药材料，药源易得，疗效显著，无任何毒副作用。
具体实施方式
实施例1
本实施例的中药汤剂由下述重量份数的药材制成：怀牛膝25份，黄芪20份，鸡骨草12份，瓜蒌子17份，肉苁蓉14份，西青果10份，苦玄参21份，宽筋藤12份，广东紫珠6份，天麻10份，苦地丁10份，枳壳13份，卜芥16份，川射干15份，杜仲20份。
制备方法及使用方法：将所述配方量中药怀牛膝、黄芪、鸡骨草、瓜蒌子、肉苁蓉、西青果、苦玄参、宽筋藤、广东紫珠、天麻、苦地丁、枳壳、卜芥、川射干、杜仲粉碎，过100-130目筛，得细粉；将粉混合均匀，置于通透袋内，用温度为25-35℃的清水浸泡24小时（优选22小时），用水量为所述细粉量的6倍；武火煮沸，文火煎煮50分钟后取出通透袋，所得液体浓缩至原体积的0.3-0.5倍，得浓缩液；浓缩液中可加入适量的蜂蜜，得到混合液，所得混合液无菌灌装，每袋100mL，既得中药汤剂。每日三次，每次1袋，饭后1小时后温服。14天为1个疗程。
实施例2
本实施例的中药汤剂由下述重量份数的药材制成：怀牛膝35份，黄芪29份，鸡骨草16份，瓜蒌子24份，肉苁蓉18份，西青果12份，苦玄参28份，宽筋藤16份，广东紫珠9份，天麻15份，苦地丁16份，枳壳21份，卜芥23份，川射干19份，杜仲28份。
制备方法及使用方法：将所述配方量中药怀牛膝、黄芪、鸡骨草、瓜蒌子、肉苁蓉、西青果、苦玄参、宽筋藤、广东紫珠、天麻、苦地丁、枳壳、卜芥、川射干、杜仲粉碎，过100-130目筛，得细粉；将粉混合均匀，置于通透袋内，用温度为25-35℃的清水浸泡24小时（优选22小时），用水量为所述细粉量的6倍；武火煮沸，文火煎煮50分钟后取出通透袋，所得液体浓缩至原体积的0.3-0.5倍，得浓缩液；浓缩液中可加入适量的蜂蜜，得到混合液，所得混合液无菌灌装，每袋100mL，既得中药汤剂。每日三次，每次1袋，饭后1小时后温服。14天为1个疗程。
实施例3
本实施例的中药汤剂由下述重量份数的药材制成：怀牛膝17份，黄芪12份，鸡骨草8份，瓜蒌子11份，肉苁蓉10份，西青果5份，苦玄参15份，宽筋藤7份，广东紫珠3份，天麻5份，苦地丁4份，枳壳5份，卜芥9份，川射干10份，杜仲12份。
制备方法及使用方法：将所述配方量中药怀牛膝、黄芪、鸡骨草、瓜蒌子、肉苁蓉、西青果、苦玄参、宽筋藤、广东紫珠、天麻、苦地丁、枳壳、卜芥、川射干、杜仲粉碎，过100-130目筛，得细粉；将粉混合均匀，置于通透袋内，用温度为25-35℃的清水浸泡24小时（优选22小时），用水量为所述细粉量的6倍；武火煮沸，文火煎煮50分钟后取出通透袋，所得液体浓缩至原体积的0.3-0.5倍，得浓缩液；浓缩液中可加入适量的蜂蜜，得到混合液，所得混合液无菌灌装，每袋100mL，既得中药汤剂。每日三次，每次1袋，饭后1小时后温服。14天为1个疗程。
临床资料
1.资料与方法
1.1临床资料
1.1.1病例选择
诊断标准参照美国风湿病学会(ACR)1987年膝OA诊断标准：(1)近1个月大多数有膝关节痛；(2)活动时有磨擦响声；(3)晨僵≤30min；(4)年龄≥38岁；(5)有骨性膨大。具(1)+(2)+(3)+(4)条或(1)+(2)+(5)或(1)+(4)+(5)即可诊断为膝OA。痹症的中医辨证诊断标准参照国家中医药管理制定的标准。其中，肝肾亏虚，经络阻塞症的具症：中年以上，腰腿酸软，膝关节疼痛，屈伸不利，不能久立远行，久痛不已，舌紫暗或有瘀斑，脉弦涩或沉紧。
1.1.2纳入标准
①符合诊断标准和中医辨证标准。②年龄为40-70岁，有明显夜间痛，病程大于1个月，均作膝关节X摄片.X线分级按Kcllgren标准达到2-3级，但不伴有肝、肾功能损害及心、肺、血液病及其他关节炎和脊柱疾病.RF阴性者。③入选前1个月均未接受过非甾体抗炎药和其他改善关节功能药治疗。
1.1.3排除标准
患者曾发生两次或两次以上的活动性消化生溃疡、胃肠道出血或胃、十二指肠溃疡；活动性胃肠道疾病(克隆氏病或溃疡性结肠炎)，或研究者认为不应使用NSAID的其他情况；患者合并其他关节炎(如RA)或活动性恶性疾病(基底细胞癌除外)；患者肝肾功能不全；患者在人选前8周内曾接受皮质类固醇激素的关节内/肌肉内注射.或透明质酸关节内注射；患者在接受首剂研究用药前30大内已经使用过任何一种研究药物。
1.1.4一般资料
将100例(男38例，女62例)按随机数字表法分为对照组(50例)和治疗组(50例)。两组患者性别、年龄、病程、关节疼痛的视觉模糊评分VAS值，Womac评分及lequesne指数差异，无统计学意义。
1.2方法
1.2.1问卷调查。所有受试对象均完成临床调查表，并逐项填表。
1.2.2给药方法
对照组：口服双醋瑞因(50mg，bid)和塞来昔布(0.2g/d)治疗，疼痛症状缓解以后停用塞来昔布，双醋瑞因继续使用，每2周为1疗程。
治疗组：服用本发明的中药汤剂，每日三次，每次1袋，饭后1小时后温服。14为1个疗程。
连续治疗2个疗程。
1.2.3疗效评价
(1)西医标准：采用国际骨关节炎的评分标准lequesne指数(包括休息时痛、运动时痛、关节压痛、关节肿胀、关节晨僵及行走能力等6局部症状指标)及Womac评分(包括疼痛分量表；关节僵硬分量表；关节分量表三个部分共24项指标)，患者VAS评分用0～100mm的比例尺，0mm为正常，100mm为最严重的状态。分别于治疗前和治疗4周后及停药2周后，评定患侧膝关节VAS值，Womac评分及lequesne指数的改善值，此3项总分平均下降≥30％，≤50％为有效，≥51％，≤75％为显效，≥76％为临床控制，≤29％为无效，总有效率表示为：改善病例数/总病例数×100％。
(2)中医标准：采用《中药新药的临床研究指导原则》将休息痛、活动痛、关节压痛、关节肿胀、关节活动度，综合计算百分数：疗效＝(治疗前总分数-治疗后总分数)/治疗前总分数×100％。综合疗效判断标准：临床治愈：疗效≥90％；显效，75％≤疗效＜90％；有效，35％≤疗效＜75％；无效，疗效指数＜35％。有效率(％)＝(治愈+显效+有效病例数)/总病例数×100％。
1.2.4检测指标的测定
(1)血液流变学测定
患者治疗前及治疗4周后清晨空腹静脉采血2mL。用MS/XW-E血流变微循环仪(成都麦塞科贸公司)，经综合传感法测定高切和低切变率下的全血粘度，用毛细管粘度计测定血浆粘度，用综合传感浊度测定相对粘度，用比浊法测定聚集指数。(2)血清IL-1β，TNF-α测定患者治疗前及治疗4周后清晨空腹静脉采血2mL，待血液凝固后立即分离血清，-20℃保存备检。采用酶标双抗体夹心ELISA法检测血清中IL-1β，TNF-α的水平，采用美国产Multiskan全自动酶标仪，配置一系列标准溶液测吸光度后，绘制标准曲线，自动计算待测样品含量。
(3)血清NO，iNOS测定
患者治疗前及治疗4周后清晨空腹静脉采血2mL，待血液凝固后立即分离血清，-20℃保存备检。NO及iNOS试剂盒购自南京建成生物工程公司，严格按照说明书操作。UV755B分光光度计530nm测定吸光度，计算结果。
(4)血浆过氧化脂质(LPO)超氧化物岐化酶(SOD)的测定
患者治疗前后清晨空腹静脉采血2.5mL，肝素抗凝，采用TBA荧光法测定血浆过氧化脂质(LPO)，采用黄嘌呤氧化酶法测定超氧化物岐化酶(SOD)。
1.2.5不良反应监测
记录治疗过程中发生的各种不良反应，包括眩晕、皮疹、胃肠道反应、注射局部红肿及全身水肿等及其持续时间和转归，治疗后查血、尿常规及肝、肾功能。
2.结果
2.1观察指标比较
治疗4周以后，两组患者的VAS值、Womac评分及lequesne指数及膝关节休息痛、活动痛、关节压痛、关节肿胀、关节活动度均有明显改善，治疗组的改善程度明显优于对照组，其差别有显著性。
2.2疗效比较
治疗4周，按西医的疗效评判标准治疗组的临床控制率达到35.3％，明显高于对照组的21.8％；按中医的疗效评判标准，治疗组的治愈率达39.5％，明显高于对照组的22.8％。
2.3观察指标比较
2.3.1血液流变学测定结果
治疗4周后治疗组的血液流变学4项指标均有显著改善，明显优于对照组，而对照组的改善不明显，
2.3.2血清IL-1β、TNF-α、NO、iNOS的测定结果
治疗4周后两组患者的IL-1β、TNF-α、NO、iNOS均有显著改善，尤以治疗组的改善更明显，差别有显著性。
2.3.3血浆LPO、SOD的测定结果
治疗4周后两组患者LPO、SOD均有显著改善，尤以治疗组的改善更明显，差别有显著性。
2.4不良反应监测结果
治疗4周期间，所有患者均未报告有主观不适，血常规、肝功能、肾功能检查亦无异常。
3.结论
本发明的中药的疗效优于传统的治疗方案(双醋瑞因+塞来昔布)而无不良反应。
典型病例
病例1：王某，女，67岁，双膝关节疼痛四年，活动受限，不能下蹲、上厕所、上下楼困难。经查：其双侧膝关节部轻度肿胀，服用本发明药物，治疗2个疗程后，后两膝关节酸痛减轻，其余症状减轻。继续服用2个疗程，痊愈，一年后随访无复发。
病例2：郭某，男，51岁，右膝关节肿痛10个月，加重2周；左膝关节肿痛3年，加重1月。以前，无明显诱因出现左膝关节的疼痛症状，以上、下楼梯时症状为重。近期出现左膝关节的肿胀、疼痛症状加剧。服用本发明中药2个疗程，双膝关节疼痛大大减轻，左膝关节肿胀减轻，右膝关节肿消失；继续服药3个疗程，复查，双膝关节肿疼消失，活动行走正常。
病例3：任某，女，62岁，经常出现膝关节疼痛，工作时偶发膝关节无法正常弯曲。后淋雨后，膝关节疼痛明显加重，走路时亦无法正常弯曲，服用本发明中药2个疗程后，膝关节疼痛症状明显减轻，继续服用4个疗程后，膝关节疼痛症状消失，痊愈，半年回访无复发。
病例4：王某，男，53岁，患膝关节炎3年，伴随有少量积液。膝关节积液影响正常晨练、生活。服用本发明中药2个疗程后，症状明显减轻，继续服用2个疗程，疼痛完全消失，检查膝关节积液消失，痊愈，一年内回访无复发。
以上实施例的说明只是用于帮助理解本发明的方法及其核心思想。应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以对本发明进行若干改进和修饰，这些改进和修饰也落入本发明权利要求的保护范围内。
Claims (6)
1.一种治疗骨关节炎的中药汤剂，其特征在于，所述中药由下述重量份数的药材制成：怀牛膝17-35份，黄芪12-29份，鸡骨草8-16份，瓜蒌子11-24份，肉苁蓉10-18份，西青果5-12份，苦玄参15-28份，宽筋藤7-16份，广东紫珠3-9份，天麻5-15份，苦地丁4-16份，枳壳5-21份，卜芥9-23份，川射干10-19份，杜仲12-28份。
2.根据权利要求1所述的中药汤剂，其特征在于，所述中药由下述重量份数的药材制成：怀牛膝20-30份，黄芪15-25份，鸡骨草10-14份，瓜蒌子13-20份，肉苁蓉12-16份，西青果7-10份，苦玄参17-25份，宽筋藤9-14份，广东紫珠4-8份，天麻7-13份，苦地丁5-15份，枳壳8-18份，卜芥12-20份，川射干12-17份，杜仲15-25份。
3.根据权利要求1所述的中药汤剂，其特征在于，所述中药由下述重量份数的药材制成：怀牛膝25份，黄芪20份，鸡骨草12份，瓜蒌子17份，肉苁蓉14份，西青果10份，苦玄参21份，宽筋藤12份，广东紫珠6份，天麻10份，苦地丁10份，枳壳13份，卜芥16份，川射干15份，杜仲20份。
4.根据权利要求1所述的中药汤剂，其特征在于，所述中药由下述重量份数的药材制成：怀牛膝35份，黄芪29份，鸡骨草16份，瓜蒌子24份，肉苁蓉18份，西青果12份，苦玄参28份，宽筋藤16份，广东紫珠9份，天麻15份，苦地丁16份，枳壳21份，卜芥23份，川射干19份，杜仲28份。
5.根据权利要求1所述的中药汤剂，其特征在于，所述中药由下述重量份数的药材制成：怀牛膝17份，黄芪12份，鸡骨草8份，瓜蒌子11份，肉苁蓉10份，西青果5份，苦玄参15份，宽筋藤7份，广东紫珠3份，天麻5份，苦地丁4份，枳壳5份，卜芥9份，川射干10份，杜仲12份。
6.制备上述任一项权利要求所述的中药汤剂的方法，其特征在于，配方量中药怀牛膝、黄芪、鸡骨草、瓜蒌子、肉苁蓉、西青果、苦玄参、宽筋藤、广东紫珠、天麻、苦地丁、枳壳、卜芥、川射干、杜仲粉碎，过100-130目筛，得细粉；将粉混合均匀，置于通透袋内，用温度为25-35℃的清水浸泡24小时（优选22小时），用水量为所述细粉量的6倍；武火煮沸，文火煎煮50分钟后取出通透袋，所得液体浓缩至原体积的0.3-0.5倍，得浓缩液；浓缩液中可加入适量的蜂蜜，得到混合液，所得混合液无菌灌装，每袋100mL，既得中药汤剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510985344.7A CN105381272A (zh) | 2015-12-25 | 2015-12-25 | 一种治疗骨关节炎的中药汤剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510985344.7A CN105381272A (zh) | 2015-12-25 | 2015-12-25 | 一种治疗骨关节炎的中药汤剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105381272A true CN105381272A (zh) | 2016-03-09 |
Family
ID=55414447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510985344.7A Withdrawn CN105381272A (zh) | 2015-12-25 | 2015-12-25 | 一种治疗骨关节炎的中药汤剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105381272A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105412437A (zh) * | 2015-12-25 | 2016-03-23 | 范明月 | 一种治疗骨关节炎的中药及其制备方法 |
| CN105477193A (zh) * | 2015-12-25 | 2016-04-13 | 范明月 | 一种治疗骨关节炎的中药散剂及其制备方法 |
| CN108904520A (zh) * | 2018-05-02 | 2018-11-30 | 广西医科大学 | 肉苁蓉多糖在制备治疗骨关节炎药物方面的应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926878A (zh) * | 2010-06-03 | 2010-12-29 | 陕西中医学院 | 一种治疗骨性关节炎的中药组合物及其制备方法 |
| CN103083443A (zh) * | 2012-03-05 | 2013-05-08 | 湖南中医药大学 | 一种治疗骨关节炎的中药组合物及其制备方法 |
| CN103566131A (zh) * | 2013-10-24 | 2014-02-12 | 安徽工贸职业技术学院 | 一种治疗骨关节炎的中药组合物及其制备方法 |
| CN103720839A (zh) * | 2014-01-20 | 2014-04-16 | 张龙强 | 一种治疗膝骨关节炎的中药 |
| CN105079721A (zh) * | 2015-09-23 | 2015-11-25 | 青岛友诚高新技术有限公司 | 一种治疗骨关节炎的中药组合物及其制备方法 |
-
2015
- 2015-12-25 CN CN201510985344.7A patent/CN105381272A/zh not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926878A (zh) * | 2010-06-03 | 2010-12-29 | 陕西中医学院 | 一种治疗骨性关节炎的中药组合物及其制备方法 |
| CN103083443A (zh) * | 2012-03-05 | 2013-05-08 | 湖南中医药大学 | 一种治疗骨关节炎的中药组合物及其制备方法 |
| CN103566131A (zh) * | 2013-10-24 | 2014-02-12 | 安徽工贸职业技术学院 | 一种治疗骨关节炎的中药组合物及其制备方法 |
| CN103720839A (zh) * | 2014-01-20 | 2014-04-16 | 张龙强 | 一种治疗膝骨关节炎的中药 |
| CN105079721A (zh) * | 2015-09-23 | 2015-11-25 | 青岛友诚高新技术有限公司 | 一种治疗骨关节炎的中药组合物及其制备方法 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105412437A (zh) * | 2015-12-25 | 2016-03-23 | 范明月 | 一种治疗骨关节炎的中药及其制备方法 |
| CN105477193A (zh) * | 2015-12-25 | 2016-04-13 | 范明月 | 一种治疗骨关节炎的中药散剂及其制备方法 |
| CN108904520A (zh) * | 2018-05-02 | 2018-11-30 | 广西医科大学 | 肉苁蓉多糖在制备治疗骨关节炎药物方面的应用 |
| CN108904520B (zh) * | 2018-05-02 | 2021-10-12 | 广西医科大学 | 肉苁蓉多糖在制备治疗骨关节炎药物方面的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103083443B (zh) | 一种治疗骨关节炎的中药组合物及其制备方法 | |
| CN101229300B (zh) | 一种治疗骨伤疾病的中药制剂 | |
| CN102240372A (zh) | 一种治疗痛风性关节炎和高尿酸血症的药物及制备方法 | |
| CN105381272A (zh) | 一种治疗骨关节炎的中药汤剂及其制备方法 | |
| CN105748543A (zh) | 一种治疗风湿性疾病的中药组合物及其制备方法 | |
| CN101002873B (zh) | 一种治疗复发性痛风的药物及其制备方法 | |
| CN102204994B (zh) | 一种治疗骨性关节炎的中药制剂及其制备方法 | |
| CN101810826B (zh) | 一种治疗肝癌的中药组合物 | |
| CN102885961B (zh) | 一种治疗风湿性关节炎、类风湿性关节炎的药物及其制备方法 | |
| CN102389561B (zh) | 一种外用热洗活血止痛中药组合物及其应用 | |
| CN103479737A (zh) | 一种治疗老年性皮肤瘙痒症的中药组合物及其应用 | |
| CN101590208B (zh) | 一种治疗类风湿关节炎的药物组合物及其制备方法 | |
| CN103182040B (zh) | 一种治疗多囊肾病的中药组合物及其制备方法 | |
| CN104096130A (zh) | 一种治疗类风湿关节炎的中药组合物 | |
| CN115814040B (zh) | 一种治疗类风湿关节炎的中药组合物及其制剂 | |
| CN114762722B (zh) | 治疗坐骨神经痛的中药组合物及其应用和中药制剂 | |
| CN103028103B (zh) | 治疗退行性膝关节病的中药制剂及其制备方法 | |
| CN100418573C (zh) | 一种治疗强直性脊柱炎的外用中药 | |
| CN105477193A (zh) | 一种治疗骨关节炎的中药散剂及其制备方法 | |
| CN105412703A (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法 | |
| CN118453799A (zh) | 一种治疗膝滑膜炎的中药组合物及其制备方法 | |
| CN114869956A (zh) | 一种用于治疗脑卒中后运动功能障碍药物组合物及其制备方法和用途 | |
| CN103239557B (zh) | 一种治疗慢性湿疹的药物及其制造方法 | |
| CN104758503B (zh) | 一种促进骨折愈合的组合物及其水煎液的制备方法 | |
| CN103381252B (zh) | 一种治疗类风湿关节炎的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160309 |